Nothing said here yet.
to join the conversation.
| Favorite Annette FSr. VP & Chief HR Officer | Sell | 2,524 | $921.3K | Tue, Sep 15 |
| Favorite Annette FSr. VP & Chief HR Officer | Sell | 2,500 | $887.5K | Mon, Sep 14 |
| Favorite Annette FSr. VP & Chief HR Officer | Sell | 2,500 | $862.5K | Fri, Sep 11 |
| Favorite Annette FSr. VP & Chief HR Officer | Sell | 2,818 | $960.4K | Tue, Sep 8 |
| Favorite Annette FSr. VP & Chief HR Officer | Sell | 2,817 | $960.1K | Tue, Sep 8 |
| Favorite Annette FSr. VP & Chief HR Officer | Sell | 2,500 | $852.0K | Tue, Sep 8 |
West Pharmaceutical Services (NYSE:WST) reported third-quarter results that exceeded its expectations, driven by continued demand for high-value product components, including those used in GLP-1 therapies and biologics.
Moby summary of West Pharmaceutical Services, Inc.'s Q3 2026 earnings call
GLP-1 demand drives HVP components to 53% of revenue with 20% organic growth.
Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 8.7% year on year to $874.5 million.
West Pharmaceutical (WST) delivered earnings and revenue surprises of +22.02% and +5.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
(AP) — West Pharmaceutical Services Inc. (WST) on Thursday reported third-quarter earnings of $214 million.
West Pharmaceutical Services has delivered a strong share price run in 2026, and that kind of move naturally raises a question about whether the current valuation lines up with the cash the business can produce over time.
Get a deeper insight into the potential performance of West Pharmaceutical (WST) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results this Thursday morning. Here’s what to expect.
WST's Q3 earnings may benefit from strong HVP demand, biologics and GLP-1 growth, but West Vantage weakness and the SmartDose divestiture could weigh on sales.
West Pharmaceutical shares have surged 36.1% YTD, fueled by strong demand for high-value components, earnings momentum and raised guidance. Can the rally continue?